Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.

Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF.

Oncogenesis. 2018 Nov 16;7(11):87. doi: 10.1038/s41389-018-0096-9.

2.

Multidrug-resistant transporter expression does not always result in drug resistance.

Le Large TYS, El Hassouni B, Kazemier G, Piersma SR, van Laarhoven HWM, Bijlsma MF, Jimenez CR, Giovannetti E.

Cancer Sci. 2018 Oct;109(10):3360-3362. doi: 10.1111/cas.13756. Epub 2018 Sep 8. No abstract available.

3.

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas.

Creemers A, Ebbing EA, Pelgrim TC, Lagarde SM, van Etten-Jamaludin FS, van Berge Henegouwen MI, Hulshof MCCM, Krishnadath KK, Meijer SL, Bijlsma MF, van Oijen MGH, van Laarhoven HWM.

Sci Rep. 2018 Sep 5;8(1):13281. doi: 10.1038/s41598-018-31548-6.

4.

The dynamics of HER2 status in esophageal adenocarcinoma.

Creemers A, Ebbing EA, Hooijer GKJ, Stap L, Jibodh-Mulder RA, Gisbertz SS, van Berge Henegouwen MI, van Montfoort ML, Hulshof MCCM, Krishnadath KK, van Oijen MGH, Bijlsma MF, Meijer SL, van Laarhoven HWM.

Oncotarget. 2018 Jun 1;9(42):26787-26799. doi: 10.18632/oncotarget.25507. eCollection 2018 Jun 1.

5.

Patched-2 functions to limit Patched-1 deficient skin cancer growth.

Veenstra VL, Dingjan I, Waasdorp C, Damhofer H, van der Wal AC, van Laarhoven HW, Medema JP, Bijlsma MF.

Cell Oncol (Dordr). 2018 Aug;41(4):427-437. doi: 10.1007/s13402-018-0381-9. Epub 2018 Jun 4.

6.

The Dutch Pancreas Biobank Within the Parelsnoer Institute: A Nationwide Biobank of Pancreatic and Periampullary Diseases.

Strijker M, Gerritsen A, van Hilst J, Bijlsma MF, Bonsing BA, Brosens LA, Bruno MJ, van Dam RM, Dijk F, van Eijck CH, Farina Sarasqueta A, Fockens P, Gerhards MF, Groot Koerkamp B, van der Harst E, de Hingh IH, van Hooft JE, Huysentruyt CJ, Kazemier G, Klaase JM, van Laarhoven CJ, van Laarhoven HW, Liem MS, de Meijer VE, van Rijssen LB, van Santvoort HC, Suker M, Verhagen JH, Verheij J, Verspaget HW, Wennink RA, Wilmink JW, Molenaar IQ, Boermeester MA, Busch OR, Besselink MG; Dutch Pancreatitis Study Group and Dutch Pancreatic Cancer Group.

Pancreas. 2018 Apr;47(4):495-501. doi: 10.1097/MPA.0000000000001018.

PMID:
29521943
7.

Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer.

Veenstra VL, Garcia-Garijo A, van Laarhoven HW, Bijlsma MF.

Cancers (Basel). 2018 Jan 27;10(2). pii: E34. doi: 10.3390/cancers10020034. Review.

8.

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel.

Steins A, Ebbing EA, Pistorius MCM, Waasdorp C, Krishnadath KK, Medema JP, Wilmink JW, Mathôt RAA, Bijlsma MF, van Laarhoven HWM.

Drug Deliv. 2017 Nov;24(1):1801-1810. doi: 10.1080/10717544.2017.1406559.

PMID:
29172757
9.

The clinical benefit of hyperthermia in pancreatic cancer: a systematic review.

van der Horst A, Versteijne E, Besselink MGH, Daams JG, Bulle EB, Bijlsma MF, Wilmink JW, van Delden OM, van Hooft JE, Franken NAP, van Laarhoven HWM, Crezee J, van Tienhoven G.

Int J Hyperthermia. 2018 Nov;34(7):969-979. doi: 10.1080/02656736.2017.1401126. Epub 2017 Nov 23.

PMID:
29168401
10.

Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.

Creemers A, Krausz S, Strijker M, van der Wel MJ, Soer EC, Reinten RJ, Besselink MG, Wilmink JW, van de Vijver MJ, van Noesel CJM, Verheij J, Meijer SL, Dijk F, Bijlsma MF, van Oijen MGH, van Laarhoven HWM.

Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):394-403. doi: 10.1016/j.bbcan.2017.08.002. Epub 2017 Aug 8. Review.

PMID:
28801248
11.

Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis.

Creemers A, Ter Veer E, de Waal L, Lodder P, Hooijer GKJ, van Grieken NCT, Bijlsma MF, Meijer SL, van Oijen MGH, van Laarhoven HWM.

Sci Rep. 2017 Jun 9;7(1):3135. doi: 10.1038/s41598-017-03304-9.

12.

Stromal SPOCK1 supports invasive pancreatic cancer growth.

Veenstra VL, Damhofer H, Waasdorp C, Steins A, Kocher HM, Medema JP, van Laarhoven HW, Bijlsma MF.

Mol Oncol. 2017 Aug;11(8):1050-1064. doi: 10.1002/1878-0261.12073. Epub 2017 Jun 5.

13.

Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies.

Le Large TYS, Bijlsma MF, Kazemier G, van Laarhoven HWM, Giovannetti E, Jimenez CR.

Semin Cancer Biol. 2017 Jun;44:153-169. doi: 10.1016/j.semcancer.2017.03.008. Epub 2017 Mar 30. Review.

14.

Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.

Ebbing EA, Steins A, Fessler E, Stathi P, Lesterhuis WJ, Krishnadath KK, Vermeulen L, Medema JP, Bijlsma MF, van Laarhoven HWM.

Gastroenterology. 2017 Jul;153(1):63-76.e14. doi: 10.1053/j.gastro.2017.03.004. Epub 2017 Mar 9.

PMID:
28286209
15.

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.

Ebbing EA, Medema JP, Damhofer H, Meijer SL, Krishnadath KK, van Berge Henegouwen MI, Bijlsma MF, van Laarhoven HW.

Oncotarget. 2016 Mar 1;7(9):10243-54. doi: 10.18632/oncotarget.7200.

16.

Feasibility and repeatability of PET with the hypoxia tracer [(18)F]HX4 in oesophageal and pancreatic cancer.

Klaassen R, Bennink RJ, van Tienhoven G, Bijlsma MF, Besselink MG, van Berge Henegouwen MI, Wilmink JW, Nederveen AJ, Windhorst AD, Hulshof MC, van Laarhoven HW.

Radiother Oncol. 2015 Jul;116(1):94-9. doi: 10.1016/j.radonc.2015.05.009. Epub 2015 Jun 3.

17.

Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract.

Damhofer H, Ebbing EA, Steins A, Welling L, Tol JA, Krishnadath KK, van Leusden T, van de Vijver MJ, Besselink MG, Busch OR, van Berge Henegouwen MI, van Delden O, Meijer SL, Dijk F, Medema JP, van Laarhoven HW, Bijlsma MF.

J Transl Med. 2015 Apr 11;13:115. doi: 10.1186/s12967-015-0469-1.

18.

The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal.

Bijlsma MF, van Laarhoven HW.

Cancer Metastasis Rev. 2015 Mar;34(1):97-114. doi: 10.1007/s10555-014-9541-1. Review.

PMID:
25566685
19.

Blocking Hedgehog release from pancreatic cancer cells increases paracrine signaling potency.

Damhofer H, Veenstra VL, Tol JA, van Laarhoven HW, Medema JP, Bijlsma MF.

J Cell Sci. 2015 Jan 1;128(1):129-39. doi: 10.1242/jcs.157966. Epub 2014 Oct 29.

Supplemental Content

Loading ...
Support Center